Studies supporting this hypothesis show that cytoplasmic CD24 inhibits ARF binding to nucleophosmin (NPM), ultimately resulting in decreased levels of p53 in prostate cancer (PC) cells [42]. This evidence concerns the gene CDKN2A and prostate carcinoma.